Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study 201038).
Latest Information Update: 22 Aug 2023
At a glance
- Drugs Tiotropium bromide (Primary) ; Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 Jun 2016 New trial record